Pharmaceuticals News

A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura's roginolisib

New Phase 3 Data Demonstrates Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

NTG Nordic Transport Group A/S – Q3 2026 Conference Call We expect to release the Q3 2026 interim results of NTG Nordic Transport Group on the evening of November 9, 2026. A webcast and conference...

FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease...

TherapiAI showcased its Biopharma AI Operating Layer at BioJapan 2026 and met with at least 113 companies from seven countries.

日本・横浜発, Oct. 09, 2026 (GLOBE NEWSWIRE) -- 台北に拠点を置き、創薬および製造向けのAIエージェントを開発しているセラピAI (TherapiAI) は、日本での事業拡大に取り組む中、今週開催されたバイオジャパン2026 (BioJapan 2026) において、同社のバイオファーマAIオペレーティングレイヤー (Biopharma AI...

FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...

TRexBio Announces Pricing of Initial Public Offering

Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)Deucrictibant IR...

Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1...